Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vintafolide in Japanese subjects with advanced solid tumor
NCT02049281Phase 1Terminated
- Sponsor
- Endocyte
- Start
- Feb 2014
- Primary completion
- May 2014
- Modality
- Prodrugs/Conditional Activator Small Molecules, Peptide-Drug Conjugates
01
Overview
Phase 1, open-label, single-arm trial of vintafolide in solid tumor, sponsored by Endocyte. Primary endpoint: Number of Participants Experiencing Dose-limiting Toxicities at 28 days. Started Feb 2014; status: terminated.
02
Drugs
vintafolide
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02049281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049281.